$4.17
+0.38 (+10.03%)
Open$4.00
Previous Close$3.79
Day High$4.25
Day Low$3.67
52W High$6.93
52W Low$1.08
Volume—
Avg Volume92.4K
Market Cap19.69M
P/E Ratio—
EPS$-3.95
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+936.0% upside
Current
$4.17
$4.17
Target
$43.20
$43.20
$28.55
$43.20 avg
$44.32
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 156.9K | 1.69M | 1.69M |
| Net Income | -27,700,541 | 118.4K | 113.8K |
| Profit Margin | -17,634.9% | 7.0% | 6.8% |
| EBITDA | -30,694,002 | 180.1K | 185.2K |
| Free Cash Flow | — | 113.7K | 84.7K |
| Rev Growth | — | -7.6% | +15.2% |
| Debt/Equity | 0.09 | 0.66 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 35.2 | 28.41B |